Clinical Trial of Potential Ulcerative Colitis Treatment Enters Next Phase

Clinical Trial of Potential Ulcerative Colitis Treatment Enters Next Phase
Theravance Biopharma announced the first dosing of a patient with moderate to severe ulcerative colitis  enrolled in its Phase 1b clinical trial, which is evaluating the investigational drug TD-1473, a pan-Janus kinase (JAK) inhibitor with the potential to treat a range of inflammatory intestinal diseases.  The clinical trial is recruiting patients. Proinflammatory cytokines play an important role in inflammatory

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *